Stockholm, 30 September 2025Vaccines for respiratory syncytial virus (RSV) reduce the risk of infection in older adults and infants, according to a new Cochrane review. The review demonstrates that vaccines for respiratory syncytial virus (RSV) are both safe and effective in protecting groups who are most at risk for serious illness, including older adults and infants. Children under the age of two months are at the highest risk of severe RSV infection and death, with older adults also vulnerable to severe disease. An international group of researchers analysed 14 clinical trials with over 100 000 participants, including older adults, pregnant people , women of childbearing age, and children. Protection for older adults and benefits for infantsResults showed strong evidence that the RSV prefusion vaccines in older adults reduce RSV-associated lower respiratory tract disease such as pneumonia and bronchitis by 77% and RSV-associated acute respiratory disease (e.g.